BioSpace News Archive

Vicore Pharma Holding AB, a pharmaceutical company developing innovative medicines for severe lung disorders such as idiopathic pulmonary fibrosis, announces top line data from a phase II study of its oral angiotensin II type 2 receptor agonist C21 in patients with systemic sclerosis and Raynaud’s phenomenon.

InteRNA Technologies, a clinical-stage biotech company developing microRNA -based therapeutics with a focus on cancer, announced that it was awarded a Clinical Innovation Credit of € 2.7 Million from the Dutch government.

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced publication of abstracts at the 2021 Annual Meeting of the American Association for Cancer Research.

Sustained pharmacodynamic effects with once-daily oral dosing, without increases in LDL cholesterol or pruritus at any dose level in healthy volunteers

Bio-Path Holdings, Inc., a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, announced an upcoming virtual poster presentation at the 2021 American Association for Cancer Research Annual Meeting, taking place April 10-15 and May 17-21, 2021.

- Positive preclinical data support continued development with strong potential in bone marrow transplant, adoptive cell therapy and gene therapy applications - Potent alpha emitter Actinium-225 targeted to CD45 cells demonstrates positive biodistribution profile and dose-dependent conditioning capabilities

Bristol Myers Squibb (NYSE:BMY) will announce results for the first quarter of 2021 on Thursday, April 29, 2021. During a conference call at 9 a.m. ET on April 29, 2021, company executives will review financial results and address inquiries from investors and analysts.

AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, today announced the appointment of Ty Howton as Chief Operating Officer and General Counsel.

I-Mab (the “Company”) (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics, today announced that a poster highlighting the mechanistic differentiation and preclinical research for uliledlimab (also known as TJD5) will be presented at the 2021 American Association for Cancer Research (AACR) Annual Meeting

PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today an e-poster presentation featuring nonclinical data of PMC-309 at American Association for Cancer Research (AACR) Annual Meeting.